ASA Non-broadcast Adjudication: Belgravia Trichological Group t/a ...The ASA is independent regulator for advertisements, sales promotion and direct m

ASA Non-broadcast Adjudication: Belgravia Trichological Group t/a ...

The ASA is independent regulator for advertisements, sales promotion and direct marketing in the UK. www.asa.org.uk/asa/adjudications/non_broadcast/Adjudication+Details.htm?Adjudication_id=41773 - 21k - Cached - Similar pages

Non-broadcast Adjudications
Belgravia Trichological Group t/a The Belgravia Centre
52 Grosvenor Gardens LondonSW1
Adjudication details. (Date, media type, sector and origin)-->
Date:
27th September 2006
Media:
Regional press
Sector:
Health and beauty
Complaint(s) from:
London
Complaint type:
Industry
Complaint
A press ad, for The Belgravia Centre, was headed "Hair loss? It's just not an option for one of Britain's top male models". It went on to claim "Belgravia's FDA approved treatment courses are proven to not only work more effectively than other treatments but are very reasonably priced ...". Consultant Trichologist Dr D Hugh Rushton believed the ad was misleading because it implied the treatments: 1. were approved or endorsed by the FDA and 2. were more effective than other treatments.
Codes section: 3.1, 7.1, 14.5, 19.1, 50.1
Adjudication
The Belgravia Centre said that they were no longer using the ad. 1. Complaint upheld The Belgravia Centre said they used Propecia and Minoxidil, products approved by the U.S. Food and Drug Administration (FDA), as part of their treatment courses. They said they had emphasised the FDA approval in their ad because they believed some other hair treatment companies advertised products with no official approval and no efficacy. They said, as far as they were aware, no other hair loss product had gained FDA approval. The ASA noted that the FDA had granted a license for the treatment of male pattern hair loss to Propecia and Minoxidil. However, we considered that the claim "Belgravia's FDA approved treatment courses ..." implied that the treatment courses themselves were FDA approved, rather than just an element of them. We concluded that the claim was misleading and told the Belgravia Centre not to use it again. On this point, the ad breached CAP Code clause 7.1 (Truthfulness) and 14.5 (Testimonials and endorsements). 2. Complaint upheld The Belgravia Centre believed Minoxidil and Propecia were proven to be the most effective treatments for hair loss and had undergone substantial clinical trials to gain FDA approval. They supplied us with reports of clinical trials on the two products. They said their treatment courses also included additional stimulants and therapies to enhance hair growth. We noted the clinical trials were based around efficacy as opposed to the effectiveness of the products in comparison with other hair loss products or treatments. We also noted that the FDA approved products were only part of the treatment courses offered by The Belgravia Centre. We received no evidence to support the effectiveness of the other elements of the courses. We considered the claim "Belgravia's ... treatment courses are proven to not only work more effectively than other treatments ..." had not been substantiated and the ad was therefore misleading. On this point, the ad breached CAP Code clauses 3.1 (Substantiation), 7.1 (Truthfulness) and 19.1 (Comparisons).

Non-broadcast Adjudications Belgravia Trichological Group t/a The Belgravia Centre

Advertising Standards Authority
The Top Navigation and Site Search section:
AAAA
Home
Accessibility
Cymraeg
Site Map
Contact Us
Search our web siteSearch
Banner Feature: Skip Navigation Links
Main Navigation
About ASA
News and events
Adjudications
Old Broadcast Rulings
Focus On
Advertising Codes
Research
Annual Report
Links
Keep Me Informed
How to Complain
Contact Us
Career Opportunities
Search
Privacy Policy
Accessibility

Visit the CAP web site.

Non-broadcast Adjudications
Belgravia Trichological Group t/a The Belgravia Centre
52 Grosvenor Gardens LondonSW1
Adjudication details. (Date, media type, sector and origin)-->
Date:
27th September 2006
Media:
Regional press
Sector:
Health and beauty
Complaint(s) from:
London
Complaint type:
Industry
Complaint
A press ad, for The Belgravia Centre, was headed "Hair loss? It's just not an option for one of Britain's top male models". It went on to claim "Belgravia's FDA approved treatment courses are proven to not only work more effectively than other treatments but are very reasonably priced ...". Consultant Trichologist Dr D Hugh Rushton believed the ad was misleading because it implied the treatments: 1. were approved or endorsed by the FDA and 2. were more effective than other treatments.
Codes section: 3.1, 7.1, 14.5, 19.1, 50.1
Adjudication
The Belgravia Centre said that they were no longer using the ad. 1. Complaint upheld The Belgravia Centre said they used Propecia and Minoxidil, products approved by the U.S. Food and Drug Administration (FDA), as part of their treatment courses. They said they had emphasised the FDA approval in their ad because they believed some other hair treatment companies advertised products with no official approval and no efficacy. They said, as far as they were aware, no other hair loss product had gained FDA approval. The ASA noted that the FDA had granted a license for the treatment of male pattern hair loss to Propecia and Minoxidil. However, we considered that the claim "Belgravia's FDA approved treatment courses ..." implied that the treatment courses themselves were FDA approved, rather than just an element of them. We concluded that the claim was misleading and told the Belgravia Centre not to use it again. On this point, the ad breached CAP Code clause 7.1 (Truthfulness) and 14.5 (Testimonials and endorsements). 2. Complaint upheld The Belgravia Centre believed Minoxidil and Propecia were proven to be the most effective treatments for hair loss and had undergone substantial clinical trials to gain FDA approval. They supplied us with reports of clinical trials on the two products. They said their treatment courses also included additional stimulants and therapies to enhance hair growth. We noted the clinical trials were based around efficacy as opposed to the effectiveness of the products in comparison with other hair loss products or treatments. We also noted that the FDA approved products were only part of the treatment courses offered by The Belgravia Centre. We received no evidence to support the effectiveness of the other elements of the courses. We considered the claim "Belgravia's ... treatment courses are proven to not only work more effectively than other treatments ..." had not been substantiated and the ad was therefore misleading. On this point, the ad breached CAP Code clauses 3.1 (Substantiation), 7.1 (Truthfulness) and 19.1 (Comparisons).
back top
Advertising Standards Authority,Mid City Place, 71 High Holborn, London, WC1V 6QT, United Kingdom

//

ASA Non-broadcast Adjudication: Belgravia Trichological Group t/a ...

ASA Non-broadcast Adjudication: Belgravia Trichological Group t/a ...
The ASA is independent regulator for advertisements, sales promotion and direct ... The Belgravia Centre said that they were no longer using the ad. ...www.asa.org.uk/asa/adjudications/non_broadcast/Adjudication+Details.htm?Adjudication_id=41773 - 21k - Cached - Similar pages

Hair Loss Gene Identified

People anxious over their hair loss might not need to worry anymore, for a gene that prevents regeneration of hair has been identified - opening a broad path to treatments for thinning locks.

A healthy individual loses about 100 strands of hair daily, with losses occurring evenly around the whole scalp. However, this hair is replaced.

The problem begins when the shedding goes beyond that number, and replacement lags.

Now, after six years of study, researchers at the University of Bonn have identified a gene that causes a rare hereditary form of hair loss - Hypotrichosis simplex - throwing open the possibility of regenerating hair.

These researchers are the first to identify a receptor that plays a role in hair growth. They now hope that their research findings will lead to new therapies that will work with various forms of hair loss.

“Although Hypotrichosis simplex is very uncommon, it may prove critical in our search for an understanding of the mechanisms of hair growth,” Nature quoted project leader Dr. Regina Betz from Bonn’s Institute of Human Genetics, as saying.

At fault is a genetic defect that prevents certain receptors on the surface of hair follicle cells from being correctly formed.

For the hair follicle to function normally, messengers must bind to these receptors, triggering a chain reaction in the cell interior.

The fact that a receptor plays a specific role in hair growth was previously unknown.

Professor Dr. Markus Nothen, who holds the Chair of Genetic Medicine at Bonn University’s Life & Brain Centre, said: “The defective receptor structure falls into the category of what are known as G-protein-coupled receptors.”

This is good news, Dr Nothen says, because, “they are particularly well suited as points of impact for drug treatments.”

The researchers have also been able to find an endogenous messenger that binds in the hair follicle to the receptor, which opens up opportunities for developing new active agents.

As part of the study, another member of the project team, dermatologist Khalid Al Aboud of the King Faisal Hospital in Makkah examined a Saudi Arabian family with Hypotrichosis simplex.

DNA samples from the parents and from nine of their 10 children - including four sufferers - were analysed, providing the researchers the key to understanding some of the fundamental mechanisms of hair growth and loss.

The researchers now hope that this individual genetic case will lead to developments that can benefit more patients.

The study is due to appear in the March edition of Nature Genetics.

Why not call 0207 976 6868 and speak to one of our trichologist who will be happy to help and advise you.

Your initial consultation and assessment are free.

So why not take advantage of our expertise and get the facts so that you can make an informed decision on what is best for the future of your hair today.

Take control of your hair loss today so that it does not control your life.

However, not all cases are treatable. But with early diagnosis and treatment you will give yourself and us the best possible chance to help you.

HairMax LaserComb: Patient Information

INTRODUCTION

Some say it is the hair that makes the man or the woman; it’s been called our crowning glory and defines our style, framing our personal presentation. For many people, losing their hair is a frustrating experience.

Thanks to the HairMax LaserComb®, there is now well founded hope for those suffering from hair loss and thinning hair.

Lexington International, LLC began developmental work on Laser PhotoTherapy over 20 years ago in Australia. Since then, the company has been at the forefront of this emerging technology. In 2001, the HairMax was introduced to the market and, from its inception, over 90% HairMax users are satisfied with their results.

In 2007, the HairMax received clearance by the US FDA for the Promotion of Hair Growth in males with certain classes of Androgenetic Alopecia (male pattern baldness). The HairMax is marketed in 90 countries and is the first and only medical device ever cleared by the FDA for “Promotion of Hair Growth”.

The handheld HairMax is available without a prescription and is a one time cost that delivers long term benefits. It is portable, easy to use, requires only three treatments per week. HairMax is even described as “therapeutic” or “soothing” by many of its users.

How the HairMax Works

The HairMax works via the principle of Photo-BioStimulation, a process by which laser energy is delivered to the hair follicle. While the exact mechanism of action is unknown, it is hypothesized that Laser PhotoTherapy stimulates growth factors within the hair follicle.

Some users report stabilization of hair fallout at the onset of treatment followed by subsequent faster and thicker new hair growth. This points to the fact that the HairMax effectively targets the hair follicle at the cellular level and in some way both speeds up the hair growth process while at the same time inducing the growth of a thicker (or terminal) hair where a thin, dying hair may have been in place previously.

PATIENT CANDIDATES

Your physician will discuss with you whether the HairMax is appropriate for treating your condition.

INDICATIONS FOR USE

The HairMax LaserComb is indicated to promote hair growth in males with androgenetic alopecia who have Norwood Hamilton Classifications of IIa to V and Fitzpatrick Skin Types I to IV.

(Studies on the use of the HairMax LaserComb in women have just been completed.)

STUDIES DEMONSTRATING

HairMax EFFECIVENESS

A clinical trial in support of the FDA submission was designed and conducted as a multicenter, randomized, sham-device controlled trial. It was conducted under strict GCP (Good Clinical Practices) guidelines and was overseen by an IRB (Independent Review Board).

The primary aim of the study was to assess the following:

promotion of hair growth
cessation of hair loss
changes in hair density
scalp overall health
safety

Study subjects used the HairMax three times per week on non-concurrent days for a total of 26 weeks. Hair density measurements were recorded at baseline and at 26 weeks, with additional clinical visits taking place at 8 and 16 weeks.

CLINICAL RESULTS

Subjects in the HairMax treatment group demonstrated a significantly greater increase in hair density (+19.80 cm2) than subjects in the placebo (sham-device) group (-7.60 cm2). Subjects in the HairMax group also had significantly better self assessments of overall hair health and regrowth than subjects in the placebo group.

There were no reports of adverse side effects from any of the subjects.

You can buy the HairMax LaserComb direct from us:

HairMax LaserComb Premier Model £335.00 RRP

HairMax LaserComb Compact SE Model £245.00 RRP

Why not call 0207 976 6868 and speak to one of our trichologist who will be happy to help and advise you.

Your initial consultation and assessment are free.

So why not take advantage of our expertise and get the facts so that you can make an informed decision on what is best for the future of your hair today.

Take control of your hair loss today so that it does not control your life.

However, not all cases are treatable. But with early diagnosis and treatment you will give yourself and us the best possible chance to help you.

Hair Loss During Military Duty Merits Compensation

If a solider incurs illness causing hair loss during mandatory military service, should the nation compensate him or not? A court ruled the government should recognize him as a man of merit so that he can be entitled to some benefits provided by the government.

A 26-year-old man, Kwon, who joined the army in December 2002, had three patches of circular balding in July, 2004, while he was training in hot weather. But he could not take immediate treatments as he was on a 10-day exercise. He received treatment after training but had lost about 80 percent of his hair.

After his condition showed no improvement, Kwon was hospitalized for better treatment, from November that year through January 2005 when he was discharged from military service.

The hair loss has expanded to his whole body since, including his eyebrows.

After the discharge, Kwon filed an application to the regional office of the Ministry of Patriots and Veterans Affairs to be recognized as a national meritorious man, saying he got the depilatory disease due to stress from the military service, including having to wear helmets in sultry weather.

But the office rejected his application in April 2006, saying the disorder was unrelated to military duty.

Kwon filed a suit with a district court in Suwon, and the local court ruled in his favor. “The hair loss seems to have occurred due to stress from his duties, considering symptoms appeared 21 months after entering the army and he did not have any diseases which may have caused the balding,” the court said in the ruling.

Similar suits are expected to follow, as Kwon said two of his peers had circular hair loss as well during training.

Once recognized as a person of national merit, one is eligible to a national pension and various other government benefits.

LaserComb Clinical Study Testimonial

You can buy the HairMax LaserComb direct from us:

HairMax LaserComb Premier Model £335.00 RRP

HairMax LaserComb Compact SE Model £245.00 RRP

Why not call 0207 976 6868 and speak to one of our trichologist who will be happy to help and advise you.

Your initial consultation and assessment are free.

So why not take advantage of our expertise and get the facts so that you can make an informed decision on what is best for the future of your hair today.

Take control of your hair loss today so that it does not control your life.

However, not all cases are treatable. But with early diagnosis and treatment you will give yourself and us the best possible chance to help you.